 |
Diabetes
and Pregnancy Stakeholder Event - 4 December 2008 |
| |
Improving pregnancy outcomes in women with pre-existing
or gestational diabetes. Open Space Event, Thursday 4 December,
9.30am - 4.30pm. Church House Conference Centre, Westminster, London
(NDST, UK) |
| |
|
|
Impact
of the UKPDS - an overview |
| |
The UK Prospective Diabetes Study (UKPDS) is
a group of clinical trials, epidemiological analyses and health-modelling
studies with an influence which can be assessed across a broad
range of health domains (PubMed) |
| |
|
|
Glucose
control in the UKPDS: what did we learn? |
| |
It also taught us that glucose control is not
enough: the central objective of therapy is to reduce vascular
risk by any means available. This commentary looks back along the
winding road that led to these conclusions (PubMed) |
| |
|
|
Autoimmune
diabetes in adults: lessons from the UKPDS |
| |
The combined evidence suggests that Latent autoimmune
diabetes in adults (LADA) is an adult-onset form of Type 1 diabetes,
rather than a separate condition or an intermediate state in a
continuum of phenotype from Type 1 to Type 2 diabetes (PubMed) |
| |
|
|
Long-Term
Follow-up after Tight Control of Blood Pressure in Type 2 Diabetes |
| |
Early improvement in blood-pressure control
in patients with both type 2 diabetes and hypertension was associated
with a reduced risk of complications, but it appears that good
blood-pressure control must be continued if the benefits are to
be maintained (NEJM, USA) |
| |
|
|
Effects
of metabolic control, patient education and initiation of insulin
therapy on the quality of life of patients with type 2 diabetes
mellitus |
| |
Improvements in metabolic control have a significant
effect on different diabetes-related quality of life domains in
patients with diabetes mellitus (Patient Education and Counseling) |
| |
|
|
Vildagliptin
well tolerated in patients with type 2 diabetes, renal impairment |
| |
Results of a pooled analysis showed that vildagliptin
is effective and well tolerated in patients with type 2 diabetes
and mild-to-moderate renal impairment (Endocrine Today) |
| |
|
|
Novo
Diabetes Trial Gets Good Results But Bad News From FDA |
| |
Novo Nordisk’s Phase
III study of liraglutide for patients with Type 2 diabetes yielded
promising results, but the drug may face an approval delay (FDA) |
| |
|
|
Amylin
pushes benefits of Byetta over Merck's Januvia |
| |
Amylin has received a boost from new data which
demonstrates that its type 2 diabetes drug Byetta provides a greater
reduction in post-meal glucose levels than Merck & Co’s Januvia (PharmaTimes) |
| |
|
